A recent study indicates that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt traditional diet and exercise plans.
Published data in a prominent health publication points out that while overweight people often shed about a fifth of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People buying such medications need to be cognizant of the danger of quick weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass within about 18 months.
Analyzing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of participants, compared the results of these new drugs with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the way of the jabs is key to understanding the heightened weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making overeating far more likely."
An Ongoing Disease?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the high risk of weight regain, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication explain a intense return of cravings.
"I experienced a switch that goes on and I was suddenly extremely hungry," recalled an individual.
This difficulty is exacerbated if users have not established lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and long-term success relies on integrated lifestyle changes.
